ReNeuron Group PLC’s (LON:RENE) Phase I/II clinical trial in the US of its blindness-causing disease, retinitis pigmentosa, has progressed to the next stage.
Following a positive data safety monitoring board review of the clinical data from the first Phase II patient cohort in the study, dosing of the second cohort of three Phase II subjects has now commenced, with the first subject in the cohort treated last week at Massachusetts Eye and Ear, in Boston.
READ: ReNeuron shares spike 20% after it provides encouraging update to Phase II eye disease trial
ReNeuron said this next dose cohort comprises patients who have a greater baseline level of visual acuity than those treated in the study thus far, thus providing a framework to better evaluate the safety of the treatment and to gain further clarity on the strong efficacy signal that was seen in the first Phase II cohort.
"We remain extremely encouraged by the positive efficacy data we have seen thus far in the Phase I/II study with our hRPC cell therapy candidate in RP patients. These results have already attracted considerable interest, particularly from those in the ophthalmology field, and we look forward to reporting further results from the study as it progresses over the coming months," said Olav Hellebø, the chief executive officer of ReNeuron.